Quantcast

Latest Merrimack Pharmaceuticals Inc. Stories

2011-08-09 00:00:28

Enrollment in Phase 1 Study of MM-302 in HER2 Positive Breast Cancer Patients Initiated by Merrimack Pharmaceuticals Cambridge, MA (PRWEB) August 08, 2011 Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase I clinical trial of MM-302, a nanotherapeutic encapsulation of doxorubicin with attached antibodies that target the ErbB2 (HER2) receptor. The Phase 1 study in patients with advanced ErbB2 positive breast cancer is designed to evaluate the...

2011-08-01 15:00:00

CAMBRIDGE, Mass., Aug. 1, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for the treatment of pancreatic cancer. MM-398 is a novel, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. MM-398 is partnered with PharmaEngine, Inc. for development and commercialization in Taiwan under the designation PEP02. (Logo:...

2011-06-30 11:12:00

CAMBRIDGE, Mass., June 30, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that it will present preclinical data on MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, and MM-398, a nanoliposomal encapsulation of irinotecan, at the 14th World Conference on Lung Cancer, taking place July 3 - 7, 2011, in Amsterdam, The Netherlands. (Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO ) MM-151 MM-151 is designed to...

2011-05-11 00:00:27

Reuniting the worldwide rights allows for a broad, global development program for MM-398 (PRWEB) May 09, 2011 Merrimack Pharmaceuticals, Inc. and PharmaEngine, Inc. (Taipei, Taiwan) today announced the signing of an agreement under which Merrimack has acquired the rights to develop and commercialize MM-398 (aka PEP02) in Europe and Asia. MM-398, originally developed by Hermes BioSciences which was acquired by Merrimack in 2009, is a highly stable nanoliposomal formulation of irinotecan....

2011-05-09 04:12:00

TAIPEI, May 9, 2011 /PRNewswire-Asia/ -- PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. announced today the execution of an agreement under which PharmaEngine grants back to Merrimack the rights to develop, manufacture, and commercialize PEP02 (known under the designation of MM-398 by Merrimack) in Asia and Europe, with the exception of Taiwan. Under the agreement, PharmaEngine will receive an upfront payment of US$10 million, and is eligible to receive up to an additional...

2011-04-20 08:59:00

CAMBRIDGE, Mass., April 20, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors. (Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO ) MM-111 is a bi-specific antibody that targets tumor cells over-expressing ErbB2/HER2. MM-111 is designed to inhibit the signaling between...

2011-04-05 10:08:00

CAMBRIDGE, Mass., April 5, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that Phase 1 results on MM-121, one of the five cancer therapeutic agents from the company's novel pipeline, will be presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) being held April 2 - 6, 2011, in Orlando, FL. (Logo: https://photos.prnewswire.com/prnh/20100913/NE63515LOGO ) MM-121 MM-121 is a fully human monoclonal antibody designed to block...

2011-04-02 00:00:28

MM-111 in pre-clinical combinations with lapatinib and endocrine therapies MM-302 in pre-clinical studies explaining its mechanism of action Cambridge, Mass. (Vocus/PRWEB) April 01, 2011 Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-111 and MM-302, two candidates from the company's novel pipeline of five cancer therapeutics, at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) being held April 2 "“ 6, 2011,...

2011-03-31 00:00:29

Robert Mulroy, President and Chief Executive Officer, will provide a company overview at Needham & Company's 10th Annual Healthcare Conference. Cambridge, MA (Vocus/PRWEB) March 30, 2011 Merrimack Pharmaceuticals today announced that it will present at Needham & Company's 10th Annual Healthcare Conference in New York City, New York. Robert Mulroy, President and Chief Executive Officer, will provide a company overview at 10:40am, Wednesday, April 6, 2011 at the New York Palace Hotel....


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related